The Conversation (0)
NeuroMetrix Announces Issuance of New U.S. Patent for DPNCheck Point-of-Care Neuropathy Test Technology
Jul. 06, 2018 08:32AM PST
Medical Device InvestingNeuroMetrix (Nasdaq:NURO) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,004,445. The patent covers novel technology that enhances DPNCheck® device performance by detecting and rejecting erroneous test conditions during nerve conduction studies. As quoted in the press release: This patent further strengthens the position of the Company in offering easy-to-use, automated …
NeuroMetrix (Nasdaq:NURO) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,004,445. The patent covers novel technology that enhances DPNCheck® device performance by detecting and rejecting erroneous test conditions during nerve conduction studies.
As quoted in the press release:
This patent further strengthens the position of the Company in offering easy-to-use, automated and accurate point-of-care neuropathy testing.
DPNCheck is a quantitative nerve conduction test that is used by physicians and health care professionals to evaluate systemic neuropathies such as diabetic peripheral neuropathy, or DPN. It is designed to be used at the point-of-care to objectively detect, stage, and monitor DPN. The device measures nerve conduction velocity and response amplitude of the sural nerve, a nerve in the lower leg and ankle. These parameters are recognized as sensitive and specific biomarkers of DPN.
